+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Transplant Diagnostics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5820290
Description Jump to:

In September 2021, Thermo Fisher Scientific added two new products to its transplant diagnostics portfolio during the American Society for Histocompatibility and Immunogenetics (ASHI) annual conference

The Global Transplant Diagnostics Market is estimated to be USD 4.39 Bn in 2023 and is expected to reach USD 6.22 Bn by 2028 growing at a CAGR of 7.21%.

Diagnostic procedures performed on organs intended for transplantation are referred to as transplant diagnostics. Both pre-transplantation and post-transplantation tests are performed. Sequence-based molecular assays, PCR-based molecular assays, and non-molecular assays are a few of the frequently utilized methods in transplant diagnosis.

The transplant diagnostics market is being driven by increasing awareness about organ donation, which is resulting in a rise in the number of organ donations and, subsequently, an increase in transplant procedures. This has created a growing demand for transplant diagnostic tests that can accurately determine the compatibility of the donor and the recipient, as well as provide ongoing monitoring for transplant recipients. Technological advancements in the field of transplant diagnostics, such as the development of new biomarkers and diagnostic techniques, are also contributing to the market growth by improving the accuracy and efficiency of these tests.

The increasing use of cross-matching and chimerism testing in pre- and post-transplantation has led to significant opportunities for the transplant diagnostics market. These diagnostic tools are crucial for assessing donor-recipient compatibility and monitoring transplant success, and as the number of transplants continues to rise worldwide, the demand for such testing is set to increase. This trend is driving market growth as more healthcare facilities and laboratories invest in advanced technologies, including automated platforms, which enhance accuracy and efficiency, lowering the risk of errors and ultimately improving patient outcomes.

However, social and ethical issues related to organ transplants significantly impact the transplant diagnostics market in various ways. One of the major issues is the limited availability of organs for transplantation, which can reduce the demand for transplant diagnostics. Furthermore, concerns about equitable access to organs and diagnostic technologies, with wealthier individuals having better access than the less affluent, can create disparities in the market. Additionally, ethical concerns related to the sources of organs, such as the use of organs from executed prisoners or organ trafficking, can also hinder the adoption of new diagnostic technologies and treatments that rely on these sources of organs. In addition, limitations in the current screening procedures for donor-recipient compatibility are impeding the growth of the transplant diagnostics market. These limitations arise from procedural and technical challenges that affect the screening process's effectiveness and efficiency, which further challenge the markets’ growth.

Market Segmentations

  • The Global Transplant Diagnostics Market is segmented based on Transplant Type, Organ Type, Technology, Type of Screening, Product, Application, End User, and Geography.
  • By Transplant Type, the market is classified into Solid Organ, Stem Cell, Soft Tissue, and Bone Marrow. Solid organ is further classified into Kidney, Liver, Heart, Lung, Pancreas, and Others.
  • The solid Organ Transplant segment holds the largest market share. The rising number of organ transplant tests and increasing funding for solid organ transplants is boosting the segments’ growth.
  • By Technology, the market is classified into Molecular and Non-Molecular.
  • The molecular technology segment has the highest market share as physicians prefer molecular assay to non-molecular. Also, due to its advantages like accuracy, efficacy, and decreased risk, HLA typing has gradually surpassed serological assays in popularity.
  • By Product, the market is classified into Reagents and Consumables, Instrument, and Software and Services.
  • Reagents and Consumables segment holds the largest market share. The SMEs claim that transplant diagnostics costs are increasing due to the increased demand for organ transplants. Also, most transplant diagnostic makers and distributors focus more on expanding markets due to their potential.
  • By Application, the market is classified into Research and Diagnostics.
  • The diagnostics application segment has the highest market share due to the increasing demand for transplant surgeries globally due to rising incidences of organ failure.
  • End User classifies the market into Hospitals and Transplant Centers, Research Laboratories and Academic Institutions, and Independent Reference Laboratories.
  • Independent reference laboratories account for the highest market share due to diagnostics laboratories' rapid modernization and automation.
  • By Geography, the market is classified into Americas, Europe, Middle East & Africa, and Asia-Pacific.
  • The Americas accounts for the highest share. This can be attributed to the rising adoption of advanced techniques, increasing healthcare expenditure, and availability of skilled professionals.

Recent Development

  • Immucor, Inc., a firm that specializes in transfusion and transplantation diagnostics, recently announced the addition of two new products to its portfolio of transplant diagnostics, proving its continued dedication to new developments in the histocompatibility sector - March 2022.
  • HepatoPredict, a predictive gene expression signature test to determine whether patients may benefit from liver transplantation, was developed in collaboration between Biocartis and Ophiomics - March 2022.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Abbott Laboratories, Alpha Biotech, Ltd., Medsystems Pvt. Ltd., Biomérieux SA, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Ireland, Luxembourg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle East and Africa (Egypt, Israel, Nigeria, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Transplant Diagnostics Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Transplant Diagnostics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Transplant Diagnostics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors.
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Increasing Awareness Leading to Increasing Organ Donations
4.2.2 Technological Advancements in the Field of Transplant Diagnostics
4.2.3 Increase in Disease Diagnosis
4.2.4 Regulatory Guidelines for Organ Transplant
4.2.5 Government and Private Collaboration into Funding Research of Target Diseases
4.3 Restraints
4.3.1 Insurance and Reimbursement Policies
4.3.2 High Cost of Organ Transplant
4.3.3 Social and Ethical Issues Related to Organ Transplant
4.4 Opportunities
4.4.1 Shift from Traditional Methods to Modern Techniques for HLA Typing
4.4.2 Increasing Demand for Organ Transplant Procedures
4.4.3 Rising Adoption of Cross-Matching and Chimerism Testing during Pre-& Post-Transplantation
4.5 Challenges
4.5.1 Significant Gap Between the Number of Organ Donors and Organs Required Annually
4.5.2 Procedural and Technical Limitations Associated with Donor-Recipient Screening
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTEL Analysis
5.4 Impact of Covid-19
5.5 Ansoff Matrix Analysis
6 Global Transplant Diagnostics Market, By Transplant Type
6.1 Introduction
6.2 Solid Organ
6.3 Stem Cell
6.4 Soft Tissue
6.5 Bone Marrow
7 Global Transplant Diagnostics Market, By Technology
7.1 Introduction
7.2 Molecular
7.2.1 PCR Based Molecular Assays
7.2.2 Sequencing Based Molecular Assays
7.3 Non-Molecular
7.3.1 Serological Assays
7.3.2 Mixed Lymphocyte Culture (MLC) Assays
8 Global Transplant Diagnostics Market, By Product
8.1 Introduction
8.2 Reagents and Consumables
8.3 Instrument
8.4 Software and Services
9 Global Transplant Diagnostics Market, By Application
9.1 Introduction
9.2 Research
9.3 Diagnostics
9.3.1 Pre-transplantation Diagnostics
9.3.2 Post-transplantation Diagnostics
10 Global Transplant Diagnostics Market, By End User
10.1 Introduction
10.2 Hospitals and Transplant Centers
10.3 Research Laboratories and Academic Institutions
10.4 Independent Reference Laboratories
11 Americas' Transplant Diagnostics Market
11.1 Introduction
11.2 Argentina
11.3 Brazil
11.4 Canada
11.5 Chile
11.6 Colombia
11.7 Mexico
11.8 Peru
11.9 United States
11.10 Rest of Americas
12 Europe's Transplant Diagnostics Market
12.1 Introduction
12.2 Austria
12.3 Belgium
12.4 Denmark
12.5 Finland
12.6 France
12.7 Germany
12.8 Italy
12.9 Ireland
12.10 Luxembourg
12.11 Netherlands
12.12 Norway
12.13 Poland
12.14 Russia
12.15 Spain
12.16 Sweden
12.17 Switzerland
12.18 United Kingdom
12.19 Rest of Europe
13 Middle East and Africa's Transplant Diagnostics Market
13.1 Introduction
13.2 Egypt
13.3 Israel
13.4 Nigeria
13.5 Qatar
13.6 Saudi Arabia
13.7 South Africa
13.8 United Arab Emirates
13.9 Rest of MEA
14 APAC's Transplant Diagnostics Market
14.1 Introduction
14.2 Australia
14.3 Bangladesh
14.4 China
14.5 India
14.6 Indonesia
14.7 Japan
14.8 Malaysia
14.9 Philippines
14.10 Singapore
14.11 South Korea
14.12 Sri Lanka
14.13 Thailand
14.14 Taiwan
14.15 Rest of Asia-Pacific
15 Competitive Landscape
15.1 Competitive Quadrant
15.2 Market Share Analysis
16 Company Profiles
16.1 Abbott Laboratories
16.1.1 Company Overview
16.1.2 Company Snapshot
16.1.3 Product Overview
16.1.4 Business Overview
16.1.5 SWOT Analysis
16.1.6 Recent Development
16.2 Alpha Biotech, Ltd.
16.2.1 Company Overview
16.2.2 Company Snapshot
16.2.3 Product Overview
16.2.4 Business Overview
16.2.5 SWOT Analysis
16.2.6 Recent Development
16.3 Bag Healthcare GmbH
16.3.1 Company Overview
16.3.2 Company Snapshot
16.3.3 Product Overview
16.3.4 Business Overview
16.3.5 SWOT Analysis
16.3.6 Recent Development
16.4 Becton, Dickinson, and Company
16.4.1 Company Overview
16.4.2 Company Snapshot
16.4.3 Product Overview
16.4.4 Business Overview
16.4.5 SWOT Analysis
16.4.6 Recent Development
16.5 Biofortuna Ltd.
16.5.1 Company Overview
16.5.2 Company Snapshot
16.5.3 Product Overview
16.5.4 Business Overview
16.5.5 SWOT Analysis
16.5.6 Recent Development
16.6 Biogenuix Medsystems Pvt. Ltd.
16.6.1 Company Overview
16.6.2 Company Snapshot
16.6.3 Product Overview
16.6.4 Business Overview
16.6.5 SWOT Analysis
16.6.6 Recent Development
16.7 Biomérieux SA
16.7.1 Company Overview
16.7.2 Company Snapshot
16.7.3 Product Overview
16.7.4 Business Overview
16.7.5 SWOT Analysis
16.7.6 Recent Development
16.8 Bio-Rad Laboratories, Inc.
16.8.1 Company Overview
16.8.2 Company Snapshot
16.8.3 Product Overview
16.8.4 Business Overview
16.8.5 SWOT Analysis
16.8.6 Recent Development
16.9 CareDx
16.9.1 Company Overview
16.9.2 Company Snapshot
16.9.3 Product Overview
16.9.4 Business Overview
16.9.5 SWOT Analysis
16.9.6 Recent Development
16.10 DiaSorin S.P.A
16.10.1 Company Overview
16.10.2 Company Snapshot
16.10.3 Product Overview
16.10.4 Business Overview
16.10.5 SWOT Analysis
16.10.6 Recent Development
16.11 F. Hoffmann-la Roche Ltd.
16.11.1 Company Overview
16.11.2 Company Snapshot
16.11.3 Product Overview
16.11.4 Business Overview
16.11.5 SWOT Analysis
16.11.6 Recent Development
16.12 Genome Diagnostics B.V.
16.12.1 Company Overview
16.12.2 Company Snapshot
16.12.3 Product Overview
16.12.4 Business Overview
16.12.5 SWOT Analysis
16.12.6 Recent Development
16.13 Hansa Biopharma AB
16.13.1 Company Overview
16.13.2 Company Snapshot
16.13.3 Product Overview
16.13.4 Business Overview
16.13.5 SWOT Analysis
16.13.6 Recent Development
16.14 Histogenetics LLC
16.14.1 Company Overview
16.14.2 Company Snapshot
16.14.3 Product Overview
16.14.4 Business Overview
16.14.5 SWOT Analysis
16.14.6 Recent Development
16.15 Hologic, Inc.
16.15.1 Company Overview
16.15.2 Company Snapshot
16.15.3 Product Overview
16.15.4 Business Overview
16.15.5 SWOT Analysis
16.15.6 Recent Development
16.16 Illumina, Inc.
16.16.1 Company Overview
16.16.2 Company Snapshot
16.16.3 Product Overview
16.16.4 Business Overview
16.16.5 SWOT Analysis
16.16.6 Recent Development
16.17 Immucor, Inc.
16.17.1 Company Overview
16.17.2 Company Snapshot
16.17.3 Product Overview
16.17.4 Business Overview
16.17.5 SWOT Analysis
16.17.6 Recent Development
16.18 Luminex Corp.
16.18.1 Company Overview
16.18.2 Company Snapshot
16.18.3 Product Overview
16.18.4 Business Overview
16.18.5 SWOT Analysis
16.18.6 Recent Development
16.19 Merck KGaA
16.19.1 Company Overview
16.19.2 Company Snapshot
16.19.3 Product Overview
16.19.4 Business Overview
16.19.5 SWOT Analysis
16.19.6 Recent Development
16.20 Olerup SSP AB
16.20.1 Company Overview
16.20.2 Company Snapshot
16.20.3 Product Overview
16.20.4 Business Overview
16.20.5 SWOT Analysis
16.20.6 Recent Development
16.21 Omixon Ltd.
16.21.1 Company Overview
16.21.2 Company Snapshot
16.21.3 Product Overview
16.21.4 Business Overview
16.21.5 SWOT Analysis
16.21.6 Recent Development
16.22 Pacific Biosciences of California, Inc.
16.22.1 Company Overview
16.22.2 Company Snapshot
16.22.3 Product Overview
16.22.4 Business Overview
16.22.5 SWOT Analysis
16.22.6 Recent Development
16.23 Qiagen N.V.
16.23.1 Company Overview
16.23.2 Company Snapshot
16.23.3 Product Overview
16.23.4 Business Overview
16.23.5 SWOT Analysis
16.23.6 Recent Development
16.24 Sigma-Aldrich Corp.
16.24.1 Company Overview
16.24.2 Company Snapshot
16.24.3 Product Overview
16.24.4 Business Overview
16.24.5 SWOT Analysis
16.24.6 Recent Development
16.25 Thermo Fisher Scientific, Inc.
16.25.1 Company Overview
16.25.2 Company Snapshot
16.25.3 Product Overview
16.25.4 Business Overview
16.25.5 SWOT Analysis
16.25.6 Recent Development
17 Appendix
17.1 Self-Assessment Form

Companies Mentioned

  • Abbott Laboratories
  • Alpha Biotech, Ltd.
  • Bag Healthcare GmbH
  • Becton, Dickinson, and Company
  • Biofortuna Ltd.
  • Biogenuix Medsystems Pvt. Ltd.
  • Biomérieux SA
  • Bio-Rad Laboratories, Inc.
  • CareDx
  • DiaSorin S.P.A
  • F. Hoffmann-la Roche Ltd.
  • Genome Diagnostics B.V.
  • Hansa Biopharma AB
  • Histogenetics LLC
  • Hologic, Inc.
  • Illumina, Inc.
  • Immucor, Inc.
  • Luminex Corp.
  • Merck KGaA
  • Olerup SSP AB
  • Omixon Ltd.
  • Pacific Biosciences of California, Inc.
  • Qiagen N.V.
  • Sigma-Aldrich Corp.
  • Thermo Fisher Scientific, Inc.

Related Topics

Copyright © 2002-2024 Research and Markets. All Rights Reserved.